. Author manuscript; available in PMC: 2023 Aug 3.

Published in final edited form as: NEJM Evid. 2022 Dec 6;2(1):10.1056/evidoa2200131. doi: 10.1056/evidoa2200131

Table 3.

Twenty-Eight–Day Mortality.^*

Cause of Mortality	Colistin plus Placebo	Colistin plus Meropenem	Difference (95% CI)^†	P Value
Overall	92/213 (43)	77/210 (37)	6.5 (−2.8 to 15.8)	0.17
Pneumonia	69/152 (45)	59/146 (40)	5.0 (−6.2 to 16.2)
BSI	23/61 (38)	18/64 (28)	9.6 (−6.8 to 26.0)
Acinetobacter baumannii	76/165 (46)	69/164 (42)	4.0 (−6.7 to 14.7)
CRE	11/34 (32)	6/35 (17)	15.2 (−4.9 to 35.3)
Pseudomonas aeruginosa	10/23 (43)	5/20 (25)	18.5 (−9.3 to 46.2)

Data are n/N (%), where n is the number of patients who died and N represents the total number of patients in the subgroup. BSI denotes bloodstream infection; CI, confidence interval; and CRE, carbapenem-resistant Enterobacterales.

^†

Differences and 95% CIs are listed as differences in percentage points of ([colistin plus placebo] – [colistin plus meropenem]). The widths of the CIs have not been adjusted for multiplicity. Thus, the CIs should not be used to reject or not reject treatment effect hypotheses.